

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL), is a rare entity characterized by extranodal involvement and association with Epstein–Barr virus (EBV). Treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like therapies alone generally does not provide durable remissions (Tse & Kwong, 2013). While chemo-radiation (for limited stage disease) or L-asparaginase-containing regimens (for advanced stage disease) have improved outcomes, ~40–50% of patients experience progression/relapse (Tse & Kwong, 2016). The median survival of advanced stage or relapsed ENKL is poor at ~6–12 months (Au *et al*, 2009; Suzuki, 2010). The role of allogeneic haematopoietic cell transplantation (allo-HCT) has been explored in a few small retrospective studies, which almost exclusively were comprised of Asian patients (Table SI). Studies evaluating allo-HCT for ENKL in a North American/European cohort are not available. Using the observational database of the Center for International Blood and Marrow Transplant Research (CIBMTR), we report here the largest analysis and the only study to include Caucasian patients.

Adult (≥ 18 years) ENKL patients undergoing allo-HCT between 2000 and 2014 were included. Central biopsy report review by expert haematopathologist was required for inclusion (details of methods, study definitions and statistical analysis are provided in Supplemental Appendix). The baseline patient-, disease- and transplantation-characteristics of 82 ENKL patients undergoing allo-HCT are described in Table I. The median age at the time of allo-HCT was 44 years (range: 20–70); 66% were male and 78% had Karnofsky performance score of $\geq 80\%$. Recipients were predominantly Caucasian (66%), 19% were of Asian ethnicity. The disease status at the time of HCT was complete remission (CR), partial remission (PR) and chemorefractory disease in 45% 30% and 12%, respectively. The majority of patients received peripheral blood grafts (89%) from matched related donors (61%). Reduced-intensity (RIC) or myeloablative conditioning (MAC) was used in 59% and 38% of cases, respectively.

Table II describes post-transplantation outcomes. With a median follow-up of 36 months (range: 1–121), the cumulative incidence of non-relapse mortality (NRM) and relapse at 3 years were 30% (95% confidence interval [CI]: 20–40) and 42% (95% CI: 32–53), respectively (Fig 1A–B). The corresponding 3-year progression-free (PFS) and overall survival (OS) were 28% (95% CI: 19–39) and 34% (95% CI: 24–45),

respectively (Fig 1C–D). No disease relapse was noted beyond the 2-year mark. At last follow-up 52 patients had died, with lymphoma relapse/progression being the most common cause of death ($n = 22$) (Table SV). Results of univariate analysis to identify factors predicting outcomes are described in Table SIII. We also built a univariate Cox proportional hazards model for each covariate (Table SIV). Recipient race (Caucasian *versus* Asian) did not significantly impact PFS (Hazard ratio [HR] = 0.92, 95% CI: 0.47–1.80, $P = 0.81$) or OS (HR = 1.17, 95% CI: 0.59–2.32, $P = 0.65$). NK-prognostic index (NK-PI) (low/low intermediate-risk *versus* high intermediate/high-risk NK-PI) was not significantly associated with the risk of disease relapse (HR = 0.81, 95% CI: 0.28–2.35, $P = 0.70$), PFS (HR = 0.89, 95% CI: 0.37–2.12, $P = 0.80$) or OS (HR = 1.11, 95% CI: 0.44–2.80, $P = 0.83$). Among patients receiving late (after >1 line of prior therapy) *versus* upfront allo-HCT (after first-line therapy), the risk of relapse (HR = 0.86, 95% CI: 0.42–1.77, $P = 0.69$), PFS (HR = 1.10, 95% CI: 0.60–1.98, $P = 0.77$) and OS (HR = 1.20, 95% CI: 0.61–2.28, $P = 0.58$) were not significantly different. Remission status at the time of allo-HCT (CR *versus* PR *versus* chemoresistant disease) did not impact the relapse risk ($P = 0.93$), PFS ($P = 0.59$) or OS ($P = 0.51$). There was no statistically significant difference between the outcomes of patients receiving RIC *versus* MAC regimens in terms of relapse (HR = 0.56, 95% CI: 0.26–1.21, $P = 0.14$), NRM (HR = 1.72, 95% CI: 0.75–3.92, $P = 0.20$), PFS (HR = 0.92, 95% CI: 0.54–1.58, $P = 0.77$) and OS (HR = 0.95, 95% CI: 0.54–1.68, $P = 0.85$).

Literature evaluating the role of allo-HCT in ENKL is limited to small retrospective studies, exclusively in Asian populations (Table SI). The largest previously reported study included 22 patients with ENKL, noting a 2-year PFS and OS of 34% and 40%, respectively (Murashige *et al*, 2005). In this study, no disease relapse was reported beyond 10 months, hinting at durable remissions with allo-HCT. In our analysis, allo-HCT in ENKL was associated with durable remission and survival in approximately one-third of the patients, with a 3-year PFS and OS of 28% and 34%, respectively and, notably, no relapses were reported beyond 2 years post-transplantation, suggesting potent graft-versus-lymphoma effects. However, disease relapse remained the main reason for treatment failure and death. This observation provides the unique opportunity for implementing better surveillance modalities in the first 2 years after transplantation or investigating novel

Table I. Baseline characteristics of patients with extranodal NK/T-cell Lymphoma, nasal type.

Variable	N = 82 (%)
Median age at HCT (range), years	44 (20–70)
Male sex	54 (66)
Karnofsky performance score before HCT	
80–100%	64 (78)
<80%	12 (15)
Unknown	6 (7)
HCT-CI	
0	35 (43)
1–2	16 (20)
≥3	13 (16)
Not collected (prior to 2007)	18 (22)
Race	
Caucasian	54 (66)
Asian	16 (19)
Others* or Unknown	12 (15)
History of prior autologous HCT	11 (13)
Median interval from diagnosis to HCT, months (range)	11 (3–137)
<1 year	47 (57)
≥1 year	33 (40)
Disease stage at diagnosis	
Stage I/II	35 (43)
Stage III/IV	22 (27)
Unknown	25 (30)
NK/T-cell Lymphoma Prognostic Index†	
Low or low-intermediate	7 (8)
High or high-intermediate	26 (32)
Unknown	49 (60)
First line of therapy	
Chemotherapy alone (n = 41)	
CHOP- or HyperCVAD-like	20 (24)
DeVIC or VIPD	4 (5)
SMILE	11 (13)
AspaMetDex	2 (2)
Gemcitabine-based	2 (2)
Others	2 (2)
Chemotherapy + radiation (n = 27)	
CHOP- or HyperCVAD-like + Radiation	14 (17)
De-VIC or VIPD + Radiation	8 (10)
SMILE + Radiation	2 (2)
AspaMetDex + Radiation	2 (2)
Other + Radiation	1 (1)
Radiation alone (n = 5)	5 (6)
Unknown 1st line therapy	9 (11)
Response to first line of therapy	
Complete remission	25 (30)
Partial remission	23 (28)
Refractory disease	18 (22)
Unknown	16 (20)
Median (range) lines of therapy before HCT	2 (1–7)
Received L/peg-asparaginase containing therapy (any time before HCT)	31 (38)
Timing of transplantation	
Upfront (after first line therapy)	25 (30)

Table I. (Continued)

Variable	N = 82 (%)
Late (>1 line of therapy prior to HCT)	49 (60)
Unknown	8 (10)
Remission status prior to HCT	
Complete remission	37 (45)
Partial remission	25 (30)
Chemorefractory	10 (12)
Untreated/unknown	10 (12)
Donor type	
Matched related donor	50 (61)
Unrelated donor	23 (28)
Umbilical cord blood	5 (6)
Haploidentical related donor	3 (4)
Missing	1 (1)
Conditioning regimen intensity	
Reduced-intensity conditioning	48 (59)
Myeloablative conditioning	31 (38)
Missing	3 (4)
Graft Source	
Bone marrow	4 (5)
Peripheral blood	73 (89)
Cord blood	5 (6)
GVHD prophylaxis	
Calcineurin inhibitor + mycophenolate mofetil	23 (28)
Calcineurin inhibitor + methotrexate ± others‡	35 (43)
Calcineurin inhibitor ± others§	16 (20)
Others¶	6 (6)
Missing	2 (2)
Donor or recipient CMV positive	57 (69)
Number of centers	43
Median follow-up of survivors (range), months	3 (1–121)

AspaMetDex, pegaspargase, methotrexate, dexamethasone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CMV, cytomegalovirus; DeVIC, dexamethasone, etoposide, ifosfamide and carboplatin; GVHD, graft-versus-host disease; HCT, haematopoietic cell transplantation; HCT-CI, haematopoietic cell transplantation-comorbidity index; Hyper-CVAD, hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone; SMILE, steroid, methotrexate, ifosfamide, L-asparaginase, etoposide; VIPD, etoposide, ifosfamide, cisplatin, dexamethasone.

*Others = African-American (n = 1), Native American (n = 3) and Other, not otherwise specified (n = 2).

†NK/T-cell Lymphoma Prognostic score – 1 point for each of the following: serum lactate dehydrogenase > normal, B symptoms at diagnosis, lymph node involvement at diagnosis, Ann Arbor stage IV at diagnosis. Low: 0, Low-intermediate: 1, High-Intermediate: 2, High: 3–4.

‡Calcineurin inhibitor + methotrexate alone (n = 31) or with sirolimus (n = 4).

§Calcineurin inhibitors alone (n = 8), or with steroid (n = 2), or with sirolimus (n = 6).

¶Mycophenolate/sirolimus (n = 1), sirolimus (n = 1), post-transplant cyclophosphamide-based (n = 3), CD34 selection (n = 1).

maintenance strategies to mitigate risk of relapse(Iqbal *et al*, 2011; Koo *et al*, 2012; Tse & Kwong, 2013; Kim *et al*, 2015; Hari *et al*, 2016).




Fig 1. Cumulative incidence of non-relapse mortality (1A) and lymphoma relapse (1B) and Kaplan–Meier estimates of progression-free survival (1C) and overall survival (1D).

Post-transplant relapse risk, NRM and survival were not affected by patient race, remission status, NK-PI, prior L-asparaginase use, timing of HCT (late vs. upfront) or conditioning intensity. The current study is the only report to evaluate allo-HCT for ENKL in a predominantly Caucasian patient cohort. The similar 3-year OS, of 35% in Caucasian and 33% in Asian patients, is noteworthy and implies the broader applicability of allo-HCT in non-Asian cohorts. In our analysis, the 3-year PFS and OS by pre-HCT remission status were similar, suggesting that even a subset of patients with chemorefractory disease can benefit from allo-HCT. The risk of disease relapse was numerically lower with MAC regimens compared to RIC (50% vs. 30%, $P = 0.07$), albeit not

statistically significant and was offset by higher NRM associated with MAC regimens (40% vs. 23%, $P = 0.12$) resulting in no difference in PFS and OS by conditioning intensity. Murashige *et al* (2005), previously reported a 2-year NRM of 30% and 20% with MAC and RIC regimens, comparable to our findings.

Being a retrospective study utilizing registry data is an inherent limitation of this analysis. The sample size limits the power to detect small differences in outcomes in our population. Notwithstanding these limitations, this CIBMTR study evaluating the role of allo-HCT in ENKL is the largest study to date and included patients only after a careful central review of biopsy reports. In conclusion, our data suggests

that allo-HCT is a viable curative option in a subset of ENKL and should be considered in advanced or relapsed/refractory disease irrespective of patient race. Relapse remains a major cause of treatment-failure, highlighting the need for active surveillance and use of pre-emptive or maintenance strategies to mitigate relapse risk.

Acknowledgements

CIBMTR Support List: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHS250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government.

*Corporate Members. The authors thank Morgan Gerontime for administrative support.

Author contributions

Conception and design: Abraham S. Kanate and Mehdi Hamadani. *Financial support:* CIBMTR. *Review of pathology reports:* Horatiu Olteanu and Mehdi Hamadani. *Collection and assembly of data:* Alyssa DiGilio and Mehdi Hamadani.

Data analysis: Kwang W. Ahn, Alyssa DiGilio and Mehdi Hamadani. *Interpretation:* All authors. *Manuscript writing:* First draft prepared by Abraham S. Kanate and Mehdi Hamadani. All authors helped revise the manuscript. *Final approval of manuscript:* All authors.

Disclosure of conflict of interest

No disclosures to report.

Abraham S. Kanate¹

Alyssa DiGilio²

Kwang W. Ahn^{2,3}

Monzr Al Malki⁴

Eric Jacobsen⁵

Amir Steinberg⁶

Nelson Hamerschlag⁷

Mohamed Kharfan-Dabaja⁸ 

Rachel Salit⁹

Edward Ball¹⁰

Qaiser Bashir¹¹

Amanda Cashen¹²

Daniel Couriel¹³

Jose Diez-Martin¹⁴

Emmanuel Katsanis¹⁵ 

Yulia Linhares¹⁶

Shahram Mori¹⁷

Richard Nash¹⁸

Attaphol Pawarode¹⁹

Miguel-Angel Perales²⁰

Colin D. Phipps²¹

Carol Richman²²

Bipin N. Savani²³

Michael Y. Shapira²⁴

Patrick Stiff²⁵

Roger Strair^{26,27}

Timothy S. Fenske^{26,27}

Sonali M. Smith²⁸

Anna Sureda²⁹

Horatiu Olteanu³⁰ 

Mehdi Hamadani² 

¹Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA, ²CIBMTR (Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA, ³Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA, ⁴City of Hope National medical Center, Duarte, CA, USA, ⁵Dana Farber Cancer Institute, Boston, MA, USA, ⁶Department of Hematology-Oncology, Mount Sinai Hospital, New York, NY, USA, ⁷Albert Einstein Hospital, Sao Paulo, Brazil, ⁸Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, ⁹Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ¹⁰University of California San Diego Medical Center, La Jolla, CA, USA, ¹¹Department of Stem Cell Transplantation, Division of Cancer Medicine, The

University of Texas MD Anderson Cancer Center, Houston, TX, USA, ¹²Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA, ¹³Utah Blood and Marrow Transplant Program, Salt Lake City, UT, USA, ¹⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain, ¹⁵University of Arizona Medical Center, Tucson, AZ, USA, ¹⁶Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA, ¹⁷Blood & Marrow Transplant Center, Florida Hospital Medical Group, Kissimmee, FL, USA, ¹⁸Colorado Blood Cancer Institute, Denver, CO, USA, ¹⁹Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA, ²⁰Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, ²¹Department of Haematology, Singapore General Hospital, Singapore, Singapore, ²²University of California Davis Cancer Center, Sacramento, CA, USA, ²³Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA, ²⁴Department of Bone Marrow Transplant, Hadassah Medical Centre, Jerusalem, Israel, ²⁵Loyola University Medical Center, Maywood, IL, USA, ²⁶Robert Wood Johnson University Hospital, New Brunswick, NJ, USA, ²⁷Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA, ²⁸Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA, ²⁹Haematology Department,

Institut Català d'Oncologia - Hospitalet, Barcelona, Spain and ³⁰Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.

E-mail: mhamadani@mcw.edu

Keywords: extranodal NK/T-cell lymphoma, allogeneic haematopoietic cell transplantation, survival, relapse, non-relapse mortality

First published online 2 August 2017

doi: 10.1111/bjh.14879

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table SI. Retrospective studies evaluating allogeneic HCT for ENKL.*

Table SII. Post-transplantation outcomes in extranodal NK/T-cell lymphoma.

Table SIII. Univariate analysis of post-transplantation outcomes.

Table SIV. Univariate Cox proportionate model of post-transplantation outcomes.

Table SV. Causes of death post allogeneic transplantation.

References

- Au, W.Y., Weisenburger, D.D., Intragumtornchai, T., Nakamura, S., Kim, W.S., Sng, I., Vose, J., Armitage, J.O. & Liang, R.; International Peripheral T-Cell Lymphoma Project. (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. *Blood*, **113**, 3931–3937.
- Hari, P., Raj, R.V. & Olteanu, H. (2016) Targeting CD38 in refractory extranodal natural killer Cell–T-cell lymphoma. *New England Journal of Medicine*, **375**, 1501–1502.
- Iqbal, J., Weisenburger, D.D., Chowdhury, A., Tsai, M.Y., Srivastava, G., Greiner, T.C., Kucuk, C., Deffenbacher, K., Vose, J., Smith, L., Au, W.Y., Nakamura, S., Seto, M., Delabie, J., Berger, F., Loong, F., Ko, Y., Sng, I., Liu, X., Loughran, T.P., Armitage, J. & Chan, W.C. (2011) Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic $\gamma\delta$ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor *in vitro*. *Leukemia*, **25**, 348–358.
- Kim, S.J., Choi, J.Y., Hyun, S.H., Ki, C.S., Oh, D., Ahn, Y.C., Ko, Y.H., Choi, S., Jung, S.H., Khong, P.L., Tang, T., Yan, X., Lim, S.T., Kwong, Y.L. & Kim, W.S.; Asia Lymphoma Study Group. (2015) Risk stratification on the basis of deauville score on PET-CT and the presence of epstein-barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. *The Lancet Haematology*, **2**, e66–e74.
- Koo, G.C., Tan, S.Y., Tang, T., Poon, S.L., Allen, G.E., Tan, L., Chong, S.C., Ong, W.S., Tay, K., Tao, M., Quek, R., Loong, S., Yeoh, K.W., Yap, S.P., Lee, K.A., Lim, L.C., Tan, D., Goh, C., Cutcutache, I., Yu, W., Ng, C.C., Rajasegaran, V., Heng, H.L., Gan, A., Ong, C.K., Rozen, S., Tan, P., Teh, B.T. & Lim, S.T. (2012) Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. *Cancer Discovery*, **2**, 591–597.
- Murashige, N., Kami, M., Kishi, Y., Kim, S., Takeuchi, M., Matsue, K., Kanda, Y., Hirokawa, M., Kawabata, Y., Matsumura, T., Kusumi, E., Hirabayashi, N., Nagafuji, K., Suzuki, R., Takeuchi, K. & Oshimi, K. (2005) Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. *British Journal of Haematology*, **130**, 561–567.
- Suzuki, R. (2010) Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. *International Journal of Hematology*, **92**, 697–701.
- Tse, E. & Kwong, Y. (2013) How I treat NK/T-cell lymphomas. *Blood*, **121**, 4997–5005.
- Tse, E. & Kwong, Y.L. (2016) Diagnosis and management of extranodal NK/T cell lymphoma nasal type. *Expert Review of Hematology*, **9**, 861–871.